A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer.Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) to placebo treatment on repeat paracentesis in symptomatic malignant ascites in participants with advanced ovarian cancerSecondary objectives: Safety, tolerability, paracentesis-related parameters, participant-reported outcome.

本研究旨在明确阿柏西普（aflibercept）在晚期化疗耐药性卵巢癌受试者中的治疗效果。主要研究目标：对比阿柏西普（ziv-阿柏西普、AVE0005、血管内皮生长因子陷阱（VEGF trap）、ZALTRAP®）与安慰剂治疗，对晚期卵巢癌伴症状性恶性腹水受试者重复腹腔穿刺术的影响。次要研究目标：安全性、耐受性、腹腔穿刺相关参数以及受试者报告结局。